Discover the complete list of Active Pharmaceutical Ingredients (APIs) manufactured or distributed by Modis Therapeutics Inc. View detailed product information, certifications, and sourcing options for each API. Connect with Modis Therapeutics Inc for compliant, high-quality pharmaceutical ingredients trusted by global clients.
Country: U.S.A.
Supplier Description: Modis Therapeutics, Inc. is a privately held biopharmaceutical company, founded in 2016, focused on developing disease-modifying therapies for rare genetic disorders, especially inherited mitochondrial diseases. Its lead program, MT1621, is a deoxynucleoside substrate enhancement therapy in clinical development for thymidine kinase 2 deficiency (TK2d), a severe mitochondrial DNA depletion syndrome.
